BioPharma Drive: Drug Pricing

SEPTEMBER 8, 2024

Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s dominant immunotherapy.

Drugs 135

Drugs 135

Drugs.com

SEPTEMBER 8, 2024

SUNDAY, Sept. 8, 2024 -- Getting older tends to go hand in hand with failing vision, but eye experts say there are things you can do to preserve your sight as you age.The risk of age-related macular degeneration (AMD) and diabetic retinopathy.

111

111

Codon

SEPTEMBER 8, 2024

In this Column, Spencer Greenberg and Amber Dawn Ace explain how charts can inadvertently manipulate reality. In 1994, the U.S. Congress passed the largest crime bill in U.S. history, called the Violent Crime Control and Law Enforcement Act. The bill allocated billions of dollars to build more prisons and hire 100,000 new police officers, among other things.

Production 101

Production Engineering Science Research 101

New Drug Approvals

SEPTEMBER 8, 2024

Palopegteriparatide Yorvipath , FDA 2024, 8/9/2024, To treat hypoparathyroidism G2N64C3385 2222514-07-8 Palopegteriparatide UNII-G2N64C3385 ACP-014 Mpeg 40000-teriparatide Palopegteriparatide [INN] Transcon parathyroid hormone (1-34) Transcon pth (1-34) Palopegteriparatide [USAN] TransCon PTH WHO 11060 Palopegteriparatide Palopegteriparatide is a human parathyroid hormone analogue corresponding to amino acid residues 1 – 34 of human parathyroid hormone, to which a methoxy polyethylene glycol (mo

FDA 62

FDA International Trials FDA Approval 62

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Perficient: Drug Development

SEPTEMBER 8, 2024

UX in Universal Design Series: Key Principles of Usability for Physical Disabilities in Health Systems In healthcare, accessibility and usability are essential to ensuring that all patients, including those with physical disabilities, receive equal care. For individuals with physical disabilities, navigating healthcare facilities and interacting with medical devices can pose significant challenges.

Treatment 52

Treatment 52

New Drug Approvals

SEPTEMBER 8, 2024

Aneratrigine 2097163-74-9 5-chloro-2-fluoro-4-[4-fluoro-2-[methyl-[2-(methylamino)ethyl]amino]anilino]- N -(1,3-thiazol-4-yl)benzenesulfonamide 5-chloro-2-fluoro-4-((4-fluoro-2-(3-(methylamino)pyridin-1-yl)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide hydrochloride Benzenesulfonamide, 5-chloro-2-fluoro-4-[[4-fluoro-2-[methyl[2-(methylamino)ethyl]amino]phenyl]amino]-N-4-thiazolyl- C 19 H 20 ClF 2 N 5 O 2 S 2 488.0 g/mol UNII 6A5ZY5LT78 WHO SYN Assignee: Daewoong Pharmaceutical Co., Ltd.

International 62

International Production Pharmaceuticals 62

New Drug Approvals

SEPTEMBER 8, 2024

Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47 fda approved 8/14/2024, To treat primary biliary cholangitis (PBC), Livdelzi Ingredient UNII CAS InChI Key Seladelpar lysine N1429130KR 928821-40-3 WTKSWPYGZDCUNQ-JZXFCXSPSA-N (+)-MBX-8025 MBX 8025 MBX-8025 MBX8025 RWJ-800025 ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACID (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVAT

FDA 62

FDA Licensing Licensing FDA Approval 62